Cure My Disease
Don't miss your cure!
Clinical trials sponsored by Astellas Pharma China, Inc., explained in plain language.
This phase 3 study tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps Chinese men with metastatic hormone-sensitive prostate cancer. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long it…
Phase: PHASE3 • Sponsor: Astellas Pharma China, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC